SC-101 clinical trials
Also written SC-101.
How each study uses SC-101 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SC-101 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SC-101
- 3
Studies by the year they started
3 studies that test it; most in 2024 (1)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Tianjin ConjuStar Biologics Co., Ltd. (2) · The First Affiliated Hospital with Nanjing Medical University (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test SC-101.
- Mar 2027Study SC-101 in Subjects With Advanced MalignanciesPhase 1 · Tianjin ConjuStar Biologics Co., Ltd.
- Jul 2027SC-101 in Subjects With Advanced NECTIN4-Amplified CancersPhase 2 · Tianjin ConjuStar Biologics Co., Ltd.
Studies
Open first, then newest update. How each study uses SC-101 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- SC-101 in Subjects With Advanced NECTIN4-Amplified CancersRecruitingPhase 2Tianjin ConjuStar Biologics Co., Ltd.NCT07080619Written as SC-101How we know
- Study SC-101 in Subjects With Advanced MalignanciesRecruitingPhase 1Tianjin ConjuStar Biologics Co., Ltd.NCT06220838Written as SC-101How we know
- Safety and Efficacy of SC101 Via Perirenal Fat Injection for Resistant Hypertension in Patients With Moderate to Severe Chronic Kidney DiseaseRecruitingPhase 1The First Affiliated Hospital with Nanjing Medical UniversityNCT07483372Written as SC101How we know
What changed recently
From the registry's own updates since Oct 22, 2026.
Started recruiting1
- SC-101 in Subjects With Advanced NECTIN4-Amplified CancersOct 29, 2026NCT07080619